Login Register Cart 0
Generic placeholder image

Recent Patents on Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 1574-891X
ISSN (Online): 2212-4071

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Is Ocular Toxicity Expected in Chloroquine/Hydroxychloroquine Prescription as a Therapeutic or Prophylactic Option in COVID-19?

Author(s): Masood Bagheri*, Zahra Rashe, Mohammad H. Ahur and Mojtaba Eidizadeh

Volume 15, Issue 2, 2020

Page: [113 - 118] Pages: 6

DOI: 10.2174/1574891X15999200819102507

Price: $65

Abstract

Background: On 11th March 2020, WHO announced novel coronavirus infectious (COVID-19) as a pandemic. New Coronavirus Pneumonia (NCP) that emerge on 31st December 2019 from China and quickly became a Public Health Emergency of International Concern (PHEIC). In the absence of evidence-based proven prophylactic or therapeutic options, chloroquine/hydroxychloroquine (CQ/HCQ) patented as first line choice in COVID- 19 treatment, which raised concerns about drug poisoning, especially ocular toxicity.

Objective: This study aims to investigate the possibility of ocular toxicity and the need for ophthalmic counseling to prescribing this therapeutic protocol.

Methods: All the articles that were most relevant to the COVID-19 therapeutic or prophylactic options and CQ derivative ocular toxicity, were founded by a literature search and were thoroughly reviewed.

Results: Anecdotal recent reports introduce CQ/HCQ as an effective therapeutic or prophylactic choice for COVID-19. Because of the short time prescribe and the insignificant cumulative dose of the drug on the one hand and a higher risk of cross-infection during an ophthalmic examination, on the other hand, an ophthalmologic consult is not recommended except in highrisk patients for retinal toxicity.

Conclusion: This study recommended ophthalmic evaluation before CQ/HCQ prescription for treatment or prophylaxis of COVID-19 only in preexisting maculopathy.

Keywords: Coronavirus, COVID19, pandemic, chloroquine, hydroxychloroquine, ophthalmology.

« Previous Next »
Graphical Abstract

[1]
Pneumonia of unkown cause. Available at: https://www.who.int/csr/don/05-january-2020-pneumonia-of-unkown-cause-china/en/ (Accessed on: Jan 5, 2020)
[2]
World Health Organization (WHO). Coronavirus disease 2019. (COVID-19) situation report-50. Available at: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200310-sitrep-50-covid-19.pdf?sfvrsn=55e904fb_2
[3]
Organisation WH. Statement on the second meeting of the international health regulations (2005) emergency committee regarding the outbreak of novel coronavirus (2019-nCoV) Available at: https://www.who.int/news-room/detail/30-01-2020-statement-on-the-second-meeting-ofthe-international-health-regulations-(2005)-emergency-committeeregarding-the-outbreak-of-novel-coronavirus-(2019-ncov)(Accessed on: July 11 2020)
[4]
Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med 2020; 35(5): 1545-9.
[http://dx.doi.org/10.1007/s11606-020-05762-w] [PMID: 32133578]
[5]
Wang C, Horby PW, Hayden FG, Gao GF. A novel coronavirus outbreak of global health concern. Lancet 2020; 395(10223): 470-3.
[http://dx.doi.org/10.1016/S0140-6736(20)30185-9] [PMID: 31986257]
[6]
Jung SM, Akhmetzhanov AR, Hayashi K, Linton NM, Yang Y, Yuan B, et al. Real-time estimation of the risk of death from novel coronavirus (COVID-19) infection: Inference using exported cases. J Clin Med 2020; 9(2): 523.
[http://dx.doi.org/10.3390/jcm9020523] [PMID: 32075152]
[7]
COVID-19 Coronavirus Pandemic. 2020. Available at: https://www.worldometers.info/coronavirus/
[8]
World Health Organization (WHO). 2020. Available at: https://www.who.int/publications-detail/clinical-management-of-severe-acuterespiratory-inection-when-novel-coronavirus-(ncov)-infetion-issuspected
[9]
Centers for Disease Control and Prevention (CDC). Interim clinical guidance for management of patients with confirmed coronavirus disease (COVID-19) Available at: https://www.cdc.gov/coronavirus/019-ncov/hcp/clinical-guidance-management-patients.html
[10]
Food and Drug Administration (FDA). Coronavirus disease 2019. Available at: https://www.fda.gov/emergency-preparedness-and-response/counterterrorism-and-emerging-threats/coronavirus-disease-2019-covid-19
[11]
Smith T, Prosser T. COVID-19 Drug TherapyPotential Options. 2020. Available at: https://www.elsevier.com/__data/assets/pdf_file/0007/988648/COVID-19-Drug-Therapy_Mar-2020.pdf
[12]
Colson P, Rolain JM, Lagier JC, Brouqui P, Raoult D. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents 2020; 55(4)105932
[PMID: 32145363]
[13]
Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, et al. Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering (Beijing) 2020. in press
[http://dx.doi.org/10.1016/j.eng.2020.03.007] [PMID: 32346491]
[14]
Khan Z, Karatas Y, Rahman H. Anti COVID-19 drugs: need for more clinical evidence and global action. Adv Ther 2020; 37(6): 2575-9.
[15]
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci 2020; 248117477
[http://dx.doi.org/10.1016/j.lfs.2020.117477] [PMID: 32119961]
[16]
Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res 2020; 178104787
[http://dx.doi.org/10.1016/j.antiviral.2020.104787] [PMID: 32251768]
[17]
Devaux CA, Rolain J-M, Colson P, Raoult D. New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 2020; 55(5)105938
[http://dx.doi.org/10.1016/j.ijantimicag.2020.105938] [PMID: 32171740]
[18]
Joyce E, Fabre A, Mahon N. Hydroxychloroquine cardiotoxicity presenting as a rapidly evolving biventricular cardiomyopathy: key diagnostic features and literature review. Eur Heart J Acute Cardiovasc Care 2013; 2(1): 77-83.
[http://dx.doi.org/10.1177/2048872612471215] [PMID: 24062937]
[19]
Yusuf IH, Sharma S, Luqmani R, Downes SM. Hydroxychloroquine retinopathy. Eye (Lond) 2017; 31(6): 828-45.
[http://dx.doi.org/10.1038/eye.2016.298]
[20]
Fihn SD, Perencevich E, Bradley SM. caution needed on the use of chloroquine and hydroxychloroquine for Coronavirus Disease 2019. JAMA Netw Open 2020; 3(4)e209035
[21]
Giner Galvañ V, Oltra MR, Rueda D, Esteban MJ, Redón J. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. Clin Rheumatol 2007; 26(6): 971-2.
[http://dx.doi.org/10.1007/s10067-006-0218-1] [PMID: 16575495]
[22]
Makin AJ, Wendon J, Fitt S, Portmann BC, Williams R. Fulminant hepatic failure secondary to hydroxychloroquine. Gut 1994; 35(4): 569-70.
[http://dx.doi.org/10.1136/gut.35.4.569] [PMID: 8175002]
[23]
Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, Hopkins JL. Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978; 17(12): 1158-75.
[PMID: 102610]
[24]
Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 2010; 62(6): 775-84.
[http://dx.doi.org/10.1002/acr.20133] [PMID: 20535788]
[25]
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF. American Academy of Ophthalmology. Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 revision). Ophthalmology 2016; 123(6): 1386-94.
[http://dx.doi.org/10.1016/j.ophtha.2016.01.058] [PMID: 26992838]
[26]
Stokkermans TJ, Trichonas G. Chloroquine And Hydroxychloroquine Toxicity 2019. StatPearls 2020. Available at: https://www.ncbi.nlm.nih.gov/books/NBK537086/
[27]
Cantor LB, Rapuano CJ, Cioffi GA. Basic and clinical science course, retina and vitreous. American Academy of Ophthalmology 2019. Available at: https://www.aao.org/Assets/ec4923aa6a904d0aa4e8a12b3bf5bdf8/636312525282830000/bcsc1718-s12-pdf
[28]
Ruamviboonsuk P, Lai TYY, Chang A, Lai CC, Mieler WF, Lam DSC. chloroquine and hydroxychloroquine retinal toxicity consideration in the treatment of COVID-19. Asia Pac J Ophthalmol (Phila) 2020; 9(2): 85-7.
[29]
Bagheri M, Rashe Z, Jafari A. A Review on 2019 novel Coronavirus pneumonia in Ophthalmology. Ocul Immunol Inflamm 2020; 27(4): 1-7.
[http://dx.doi.org/10.1080/09273948.2020.1766084] [PMID: 32634041]
[30]
Xie X, Li Y, Chwang AT, Ho PL, Seto WH. How far droplets can move in indoor environments-revisiting the Wells evaporation-falling curve. Indoor Air 2007; 17(3): 211-25.
[http://dx.doi.org/10.1111/j.1600-0668.2007.00469.x] [PMID: 17542834]

Rights & Permissions Print Cite
Article Metrics
32
© 2024 Bentham Science Publishers | Privacy Policy